Hassan: Congress' duty to fund FDA

Share this article:
Schering-Plough chairman and CEO Fred Hassan has set out an agenda for the newly elected US Congress when it convenes in January.

In remarks to the Cardiovascular Summit of more than 150 cardiovascular experts in advance of the American Heart Association's annual Scientific Sessions, Hassan said the lawmakers have a “moral obligation” to play for the long term. 

Hassan called on the new Congress to recognize that biopharmaceutical research is vital to the success of the US economy.

Hassan said the key to sustaining biopharmaceutical research is to preserve the strength and independence of FDA.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

Five things for Pharma Marketers to know: Friday, August 29

Five things for Pharma Marketers to know: Friday, ...

Takeda closes out a good-news, bad-news kind of week, AstraZeneca adds a new clinical trial for its experimental PD-1, and researchers link a funeral to the Ebola outbreak.

Amgen sends PCSK9 to FDA

Amgen sends PCSK9 to FDA

Evolocumab holds the FDA's first filed biologics license application for the class.

Consultants expect M&A tempo to continue

Consultants expect M&A tempo to continue

PwC anticipates that divestitures will fuel late-2014 deals, but notes that the noise around early deals and the financials don't fully match up.